

iTOC11
CONFERENCE
www.itoc-conference.eu
11TH IMMUNOTHERAPY
OF CANCER CONFERENCE

THE LEADING INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE IN EUROPE

11th ImmunoTherapy of Cancer Conference
April 3 - 5, 2025 • Munich, Germany



CCC MÜNCHEN
COMPREHENSIVE
CANCER CENTER



WOLFGANG
WILMANN'S
STIFTUNG



Deutsches Konsortium für
Translationale Krebsforschung



CECOG ACADEMY
Central European Cooperative Oncology Group

SCIENTIFIC PROGRAMME



JOIN US AT ITOC11!

The 11th ImmunoTherapy of Cancer Conference (ITOC11) to be held from April 3 - 5, 2025 is a European meeting providing a global platform for translational research in the field of immuno-oncology as well as a forum for discussion of early clinical translation and to address its unique challenges.

ITOC11 is organised by the WMA GmbH in scientific cooperation with the ITOC Association, the Tumor Centre in Munich (TzM), the German Cancer Consortium (DKTK), the CECOG Academy, the CAHON, the Wolfgang Wilmanns Stiftung as well as the Comprehensive Cancer Center Munich (CCCM) in Munich.

The main goal of the series of ITOC conferences is to provide a unique platform for discussions where all those dedicated to the immunotherapy of cancer can exchange their knowledge and latest findings to advance the oncology drug development and delivery.



See you there!



ITOC11 COMMITTEES

ITOC11 Conference President

- Michael von Bergwelt (LMU, CCC, DKTK, Munich, Germany)

ITOC11 Chairmen of the Scientific Committee


- Sebastian Kobold (Ludwig-Maximilians-Universität, Munich, Germany)
- Volkmar Nuessler (TZM, Munich, Germany)

ITOC11 Scientific Committee

- Niroshana Anandasabapathy (Weill Cornell New York, NY, United States)
- Michael Bergmann (Medical University Vienna, Austria)
- Mascha Binder (Universitätsspital Basel, Switzerland)
- Tanja D. de Gruijl (Cancer Center Amsterdam, The Netherlands)
- Alexander Eggermont (Cancer Center Amsterdam, The Netherlands)
- Ulrich Jäger (Medical University of Vienna, Austria)
- Sebastian Kobold (Ludwig-Maximilians-Universität, Munich, Germany)
- Volkmar Nuessler (Munich, Germany)
- Johanna Olweus (Institute for Cancer Research, University of Oslo, Norway)
- Chong-Xian Pan (Harvard Medical School, Boston, MA, United States)
- Pedro Romero (Translational Tumor Immunology Group, University of Lausanne, Switzerland)
- José Saro (CMO LCB-Novimmune, Switzerland)
- Stefani Spranger (Koch Inst. for Integrative Cancer Research at MIT, Cambridge, MA, United States)
- Marion Subklewe (Ludwig-Maximilians-Universität, Munich, Germany)
- Eric Tartour (Hopital Européen Georges-Pompidou, Paris, France)
- Christoph Zielinski (Medical University of Vienna, Austria)

ITOC Association Board Members

- Sebastian Kobold (Ludwig-Maximilians-Universität, Munich, Germany)
- Volkmar Nuessler (Munich, Germany)
- Michael von Bergwelt (LMU, CCC, DKTK, Munich, Germany)
- Christoph Zielinski (Medical University of Vienna, Austria)



08.30 **Registration Opens**

09.30 - 09.40 **Welcome Address:** Michael von Bergwelt, Munich, Germany

09.40 - 11.10 **Plenary Session 1: Tumor Immunology Inside: Novel Players**

09.40 – 10.10 01.01. Neutrophils in cancer
Mikael Pittet, Geneva, Switzerland

10.10 – 10.40 01.02. Dendritic cells as orchestrators of cancer immunity
Niroshana Anandasabapathy, New York, NY, United States

10.40 – 11.10 01.03. Tregs in the cancer environment
Eliane Piaggio, Paris, France

11.10 - 11.40 Coffee Break

11.40 - 13.10 **Plenary Session 2: Expect the Unexpected: Factors Influencing Immune Therapies**

11.40 - 12.10 02.01. The influence of circadian rhythm on IO agent efficacy
Christoph Scheiermann, Geneva, Switzerland

12.10 - 12.40 02.02. Androgen influence on immunotherapy
Megan Ruhland, Portland, OR, United States

12.40 - 13.10 02.03. Local production of glucocorticoids in cancer and its therapeutic relevance
Matthew Taves, Bethesda, MD, United States

13.10 - 13.40 **Satellite Symposium - Slot 1**

13.40 - 15.00 Lunch & Poster Viewing

15.00 - 17.00 **Plenary Session 3: New Targets and New Leads**

15.00 - 15.30 03.01. Proteostatic Stress Response as Novel Opportunity for Cancer Immunotherapy
Zihai Li, Columbus, OH, United States

15.30 - 16.00 03.02. MultiOmics in pushing the frontiers in understanding the tumor microenvironment: Single cell resolution imaging
Matteo Iannacone, Milan, Italy

16.00 – 16.15 03.03. Talk from Submitted Abstracts

16.15 – 16.30 03.04. Talk from Submitted Abstracts

16.30 – 16.45 03.05. Talk from Submitted Abstracts

16.45 – 17.00 03.06. Talk from Submitted Abstracts

17.00 - 18.00 **Plenary Session 4: Polyspecific Antibody Derivatives**

17.00-17.30 04.01. TCR and TCR mimetics x CD3 bispecific antibodies: Expand the reach of antibodies to intracellular targets
Guillem Argilés, New York, NY, United States

17.30-18.00 04.02. Bispecific gamma-delta T-cell engagers (Gammabodies) against cancer
Hans van der Vliet, Amsterdam, The Netherlands

18.00 - 20.00 **Networking Event and Poster Viewing (at the venue)**



08.00 – 08.30 Satellite Symposium - Slot 2

08.30 – 09.30 Plenary Session 5: Pro and Con: Local vs Systemic Immunotherapy

08.30 – 09.00 05.01. Pro-local immunotherapies
Louisa von Baumgarten, Munich, Germany

09.00 – 09.30 05.02. Pro systemic immunotherapy
Mascha Binder, Basel, Switzerland

09.30 – 10.30 Plenary Session 6: Playing with the Devil: Nociception in Cancer Immunotherapy

09.30 – 10.00 06.01. Triggering alpha2adrenergic receptors for tumor rejection
Jingjing Zhu, Louvain, Belgium

10.00 – 10.30 06.02. Neuro-immune regulation of ILC function in anti-tumor immunity
Camilla Jandus, Geneva, Switzerland

10.30 – 11.00 Coffee Break

11.10 – 12.30 Plenary Session 7: Immune Monitoring – Omics Technology

11.00 – 11.30 07.01. Spatial profiling of the immune contexture in cancer: a novel translational way to attack 'cold' tumors
Niels Halama, Heidelberg, Germany

11.30 – 12.00 07.02. Resolving the HLA-ligandome in cancer
Juliane Walz, Tübingen, Germany

12.00 – 12.30 07.03. Liquid immunotranscriptomics-derived biomarkers for monitoring response to immunotherapy in metastatic cancer
Pedro Romero, Lausanne, Switzerland

12.30 - 13.00 Satellite Symposium - Slot 3 | Option 1 (30min)

12.30 - 13.30 Satellite Symposium - Slot 3 | Option 2 (60min)

13.00/13.30 – 14.30 Lunch & Poster Viewing

14.30 – 15.15 **Plenary Session 8: ITOC 11 Lifetime Achievement Award**
Robert D. Schreiber, St. Louis, MO, United States


15.15 - 16.30 Plenary Session 9: Advancing Cancer Vaccines

15.15 – 15.45 09.01. Neoantigen selection in tumor and lessons from flu
Paul G. Thomas, Memphis, TN, United States

15.45 – 16.15 09.02. Dysfunctional translation generates aberrant, immunogenic peptides
Wouter Scheper, Amsterdam, The Netherlands

16.15 – 16.30 09.03. Talk from Submitted Abstracts

16.30 - 17.00 Coffee Break





FRIDAY, APRIL 4, 2025

17.00 - 18.00 Plenary Session 10: Young Researcher Session (from submitted abstracts)

17.00 – 17.15 10.01. Talk from Submitted Abstracts

17.15 – 17.30 10.02. Talk from Submitted Abstracts

17.30 – 17.45 10.03. Talk from Submitted Abstracts

17.45 – 18.00 10.04. Talk from Submitted Abstracts

18.00 - 19.00 Poster Viewing with Presenters

19.15 ITOC 11 Conference Dinner



08.00 – 09.00 Plenary Session 11: What Cellular Therapies Need to Work

08.00 – 08.30 11.01. The role of preconditioning in T cell therapy
Michal Besser, Tel Aviv, Israel

08.30 – 09.00 11.02. The role of myeloid cells in CAR T cell failure
Camille Bigenwald, Villejuif, France

09.00 – 10.30 Plenary Session 12 Engineering novel Cellular Immunotherapies

09.00 – 09.30 12.01. Novel targets of TCR therapies
Johanna Olweus, Oslo, Norway

09.30 – 10.00 12.02. Adoptive Cell Therapy, ways to enhance them
Sabine Heitzeneder, Stanford, CA, United States

10.00 – 10.30 12.03. RORing cancer with novel CAR T cells
Michael Hudecek, Würzburg, Germany

10.30 – 11.00 Coffee Break

11.00 – 12.30 Plenary Session 13: Advancing Cellular Therapies with Combinations

11.00 – 11.30 13.01. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors
Andreas Mackensen, Erlangen, Germany

11.30 – 12.00 13.02. Targeting TGFbeta-activated kinase-1 activation in microglia to reduce neurotoxicities of CAR T cell therapies
Robert Zeiser, Freiburg, Germany


12.00 – 12.15 13.03. Talk from Submitted Abstracts

12.15 – 12.30 13.04. Talk from Submitted Abstracts

12.30 – 12.45 13.05. Talk from Submitted Abstracts

12.45 – 13.15 Plenary Session 14: Best Poster Awards & Closing Remarks

13.15 – 14.15 Lunch & Farewell



SAVE THE DATES!

Mark your calendars and save the dates for the

11th ImmunoTherapy of Cancer Conference in 2025!

Join us as we convene once again to advance research, foster collaboration, and drive innovation in the field of cancer immunotherapy. Get ready to connect with leading experts, explore cutting-edge discoveries, and shape the future of cancer treatment.

Stay tuned for more details on the 2025 conference that promises to inspire, educate, and propel us closer to our shared goal of conquering cancer through immunotherapy.

#ITOC2025 #Immunotherapy #SaveTheDate

